Marine-Derived Compounds Emerge as Dual BTK-FGGR Inhibitors for Precision Oncology
Background
Targeting specific kinases like Bruton's tyrosine kinase (BTK) and fibroblast growth factor receptor (FGFR) is a cornerstone of precision oncology, yet resistance and off-target effects remain challenges for many existing therapies. BTK is crucial in B-cell signaling and proliferation, while FGFR plays a vital role in cell growth, differentiation, and angiogenesis, often dysregulated in various cancers. Marine natural products (MNPs) offer a vast, underexplored reservoir of structurally diverse compounds with unique pharmacological activities, presenting an opportunity to discover novel, potent kinase inhibitors that could overcome current therapeutic limitations.
Study Design
This comprehensive literature review synthesized findings from 110 closely related studies published between 2015-2025 on marine-derived dual BTK-FGFR inhibitors. Researchers systematically retrieved relevant studies from major scientific databases, including ScienceDirect, PubMed, and Google Scholar. The review focused on identifying marine natural products with demonstrated inhibitory activity against both BTK and FGFR pathways, assessing their chemical structures, mechanisms of action, and current developmental stages in oncology.
Results
The review identified a diverse array of marine-derived compounds, including peptides, terpenoids, alkaloids, and polyketides, that effectively inhibit the BTK and FGFR pathways. These compounds demonstrated significant cytotoxicity against multiple cancer cell lines in various preclinical models. Several of these promising agents are currently in preclinical or early-phase clinical development, showcasing their potential as novel anticancer therapeutics. Computational simulations played a crucial role, accurately predicting bioactivity and refining molecular interaction models, which assisted in identifying optimal scaffolds for targeted therapy development. The unique chemical scaffold structures of these marine metabolites were highlighted for their effective modification of BTK and FGFR activity.
These compounds were selected as potential lead candidates for precision oncology therapies based on computational analyses and newly developing evidence supporting their efficacy as kinase inhibitors, effectively decreasing cancer cell growth.
Key Findings
- Marine-derived compounds, including peptides and terpenoids, inhibit
BTKandFGFRpathways. - These compounds exhibit cytotoxicity against multiple cancer cell lines in preclinical studies.
- Several marine-derived
BTK-FGFRinhibitors are in preclinical or early clinical development. - Computational simulations predict bioactivity and refine molecular interactions for these compounds.
- Unique marine chemical scaffolds offer effective modification of
BTKandFGFRactivity.
Why It Matters
This review highlights a critical shift towards leveraging marine biodiversity for novel cancer therapeutics, offering a fresh pipeline for precision oncology. For biohackers and clinicians, this suggests future therapeutic options with potentially unique mechanisms of action, possibly overcoming resistance seen with current kinase inhibitors. The emphasis on computational approaches means drug discovery can be significantly accelerated, moving from raw natural products to refined lead candidates more efficiently. While these compounds are mostly in preclinical or early clinical stages, their distinct chemical scaffolds could lead to more selective and potent BTK and FGFR inhibition, ultimately translating into more effective and less toxic treatments for various cancers. This opens avenues for combining these novel agents with existing protocols once they advance through clinical trials.
marine-compounds
btk-inhibitor
fgfr-inhibitor
oncology
cancer
review